Diquafosol sodium ophthalmic solution,
does it really help with Improvement of dry-eye symptoms by increasing fluid and mucin secretion?
research showsDiquafosol sodium ophthalmic solution is rated C because evidence is limited to small short-term changes in staining, tear-film measures, and subjective endpoints. In the 14-trial meta-analysis, eight postoperative cataract-surgery trials found no significant OSDI benefit. A nine-trial meta-analysis versus hyaluronic acid found small differences: OSDI -3.59 points, Schirmer +1.08 mm, and tear-film breakup time +0.60 seconds. Long-term clinical efficacy and disease modification remain unestablished.
ads claimMarketing can turn short-term test improvement into a claim that the drug creates tears and mucin to cure dry eye at its root. The evidence applies to short-term symptom, staining, and tear-film improvement in selected patients using a prescription product, not every cause of dry eye or guaranteed long-term recovery.
Useful facts when choosing a product
- Diquafosol sodium 3% ophthalmic solution, sold under names including Diquas, is a prescription P2Y2 receptor agonist that promotes fluid and mucin secretion from the conjunctiva.
- Unlike the nonprescription trehalose artificial tears in verdict 581, this is a prescription ophthalmic drug. Dosing and preservative content can differ by product, so the prescription and label take priority.
- Instillation can cause irritation, discharge, itching, redness, pain, or a foreign-body sensation. The bottle tip should not touch the eye or skin.
- Patients using other eye drops or contact lenses should confirm spacing and lens instructions with a clinician. Worsening pain, reduced vision, or failure to improve warrants reassessment.
What the research actually shows
A 14-trial meta-analysis reported short-term signals in ocular-surface staining, tear-film measures, and tear production, but eight postoperative cataract-surgery trials showed no significant OSDI benefit. A nine-trial meta-analysis against hyaluronic acid found small differences of -3.59 OSDI points, +1.08 mm on Schirmer testing, and +0.60 seconds in tear-film breakup time. Individual placebo- and active-controlled trials mainly measured four- to six-week staining and tear-film outcomes rather than long-term quality of life or disease course.
Why this is classified as C (58)
Multiple trials show short-term staining and tear-film signals, but OSDI was null in the postoperative subset and the OSDI, Schirmer, and tear-film differences versus hyaluronic acid were small. Evidence remains limited to short-term subjective and surrogate outcomes without established long-term clinical efficacy. The applicable evidence ceiling is C, giving 58 points.
Counterpoint. The drug can be a useful prescription option when tear-film instability or mucin deficiency contributes to disease. Meibomian-gland dysfunction, autoimmune disease, medication effects, and postoperative dry eye may still require cause-specific treatment and eyelid or environmental measures.
Rejudgment record. Reassessment (cross-check reflected) — Applied C because eight postoperative trials found no significant OSDI benefit, a nine-trial comparison with hyaluronic acid showed only small OSDI, Schirmer, and tear-film differences, and evidence remained confined to short-term subjective and surrogate outcomes without long-term clinical efficacy
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improvement in dry-eye symptoms, corneal staining, and tear-film measures | C | Short-term surrogate signals are positive, but OSDI was null and effects were small. |
| Disease modification and long-term quality-of-life improvement | ? | Trials of long-term clinical course are absent. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Liu S et al. 2023 | Systematic review and meta-analysis of randomized trials | 14 | Academic study; conflicts varied across included trials | Corneal and conjunctival staining, Schirmer testing, tear-film breakup time, symptoms, and adverse events | Three-percent diquafosol showed an overall favorable signal across ocular-surface, tear-film, and symptom measures. | Key short-term synthesis |
| Matsumoto Y et al. 2012 | Multicenter randomized double-masked placebo-controlled phase 2 trial | 286 | Development-trial context with limited independence | Four-week fluorescein and rose-bengal staining, tear-film breakup time, and subjective symptoms | The 3% group improved fluorescein and rose-bengal staining and symptoms versus vehicle, but tear-film breakup time did not differ significantly. | Direct placebo-controlled evidence |
| Takamura E et al. 2012 | Multicenter randomized double-masked active-controlled phase 3 trial | 286 | Phase 3 development context | Four-week fluorescein and rose-bengal staining and adverse events | Diquafosol was noninferior for fluorescein staining and superior for rose-bengal staining, but outcomes were staining surrogates. | Active-control replication evidence |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Diquafosol sodium ophthalmic solution x dry-eye symptom improvement — Evidence Grade C·58. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/diquafosol-sodium-dry-eye-tear-mucin-secretion/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.